# US 4,394,502 A · Immunotherapeutic agent for tumors comprising lipopolysaccharide as an active component

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 4,394,502 A
- Document ID: US4394502A
- Status: Granted
- Kind: A
- Application number: 06/293,999
- Filed: 1981-08-18
- Granted: 1983-07-19
- Earliest claimed: 1979-07-04
- Inventors: Chisato Maruyama
- Web page: https://patentgrep.com/patent/US4394502A

## CPC

- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 35/00: Antineoplastic agents
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is a novel immunotherapeutic agent for tumors, which comprises as an active component a lipopolysaccharide derived from human tubercle bacillus or a lipopolysaccharide formed by chemically modifying said lipopolysaccharide.

## Claims

### Claim 1

An immunotherapeutic agent for tumors, which comprises as an effective component lipopolysaccharide comprising, arabinomannan as a polysaccharide and fatty acids bonded to said arabinomannan through an ester linkage, the fatty acid content in said lipopolysaccharide being 3 to 28%, said lipopolysaccharide being obtained by hot water extraction and purification of the cell body of human tubercle bacillus, Mycobacterium tuberculosis strain Aoyama B or Mycobacterium tuberculosis strain H.sub.37 R.sub.v.

### Claim 2

An immunotherapeutic agent for tumors, which comprises as an effective component lipopolysaccharide prepared by bonding a fatty acid to arabinomannan through an ester linkage, said arabinomannan being obtained by alkali extraction and purification of the cell body of human tubercle bacillus, Mycobacterium tuberculosis strain Aoyama B or Mycobacterium tuberculosis strain H.sub.37 R.sub.v, the fatty acid content in said lipopolysaccharide being 3 to 28%.

### Claim 3

An immunotherapeutic agent for tumors, which comprises as an effective component lipopolysaccharide prepared by bonding a fatty acid to lipoarabinomannan through an ester linkage, said lipoarabinomannan being obtained by hot water extraction and purification of the cell body of human tubercle bacillus, Mycobacterium tuberculosis strain Aoyama B or Mycobacterium tuberculosis strain H.sub.37 R.sub.v, the fatty acid content in said lipopolysaccharide being 3 to 28%.

### Claim 4 (depends on 1)

An immunotherapeutic agent for tumors according to claim 1 wherein said fatty acids are palmitic acid, myristic acid, stearic acid, tuberculostearic acid, heptadecanoic acid, oleic acid and linoleic acid and said lipopolysaccharide has a monosaccharide composition of 30 to 74% of arabinose, 20 to 50% of mannose, 0 to 10% of glucose and 0 to 13% of galactose.

### Claim 5 (depends on 2, 3)

An immunotherapeutic agent for tumors according to claim 2 or 3 wherein fatty acid is selected from the group consisting of palmitic acid and stearic acid and said lipopolysaccharide has a monosaccharide composition of 30 to 74% of arabinose, 20 to 50% of mannose, 0 to 10% of glucose and 0 to 13% of galactose.